CN101395478B - 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途 - Google Patents

用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途 Download PDF

Info

Publication number
CN101395478B
CN101395478B CN2007800040238A CN200780004023A CN101395478B CN 101395478 B CN101395478 B CN 101395478B CN 2007800040238 A CN2007800040238 A CN 2007800040238A CN 200780004023 A CN200780004023 A CN 200780004023A CN 101395478 B CN101395478 B CN 101395478B
Authority
CN
China
Prior art keywords
prongf
cancer
cells
thyroid
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800040238A
Other languages
English (en)
Chinese (zh)
Other versions
CN101395478A (zh
Inventor
G·肖凯-凯斯狄拉维斯基
Y·德蒙
H·亨德尔马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Universite Lille 1 Sciences et Technologies
Original Assignee
Biomerieux SA
Universite Lille 1 Sciences et Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA, Universite Lille 1 Sciences et Technologies filed Critical Biomerieux SA
Publication of CN101395478A publication Critical patent/CN101395478A/zh
Application granted granted Critical
Publication of CN101395478B publication Critical patent/CN101395478B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CN2007800040238A 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途 Active CN101395478B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0600851 2006-01-31
FR0600851A FR2896881B1 (fr) 2006-01-31 2006-01-31 Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
PCT/FR2007/050708 WO2007088305A1 (fr) 2006-01-31 2007-01-30 Procede de dosage du prongf pour le diagnostic in vitro du cancer en particulier du cancer du sein, de la thyroide ou du poumon et utilisation du prongf en therapie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013103889291A Division CN103446585A (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途

Publications (2)

Publication Number Publication Date
CN101395478A CN101395478A (zh) 2009-03-25
CN101395478B true CN101395478B (zh) 2013-08-28

Family

ID=36741378

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2007800040238A Active CN101395478B (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途
CN2013103889291A Pending CN103446585A (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013103889291A Pending CN103446585A (zh) 2006-01-31 2007-01-30 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途

Country Status (7)

Country Link
US (3) US8008009B2 (enExample)
EP (1) EP1982192B1 (enExample)
JP (2) JP5091876B2 (enExample)
CN (2) CN101395478B (enExample)
ES (1) ES2471126T3 (enExample)
FR (1) FR2896881B1 (enExample)
WO (1) WO2007088305A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
FR2944019B1 (fr) * 2009-04-03 2011-04-22 Biomerieux Sa Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal.
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
CN101782585A (zh) * 2010-02-10 2010-07-21 广州医学院 肺癌组织蛋白印迹膜片及其制备方法
WO2011159762A1 (en) * 2010-06-15 2011-12-22 Cornell University Methods of limiting microvascular damage following acute myocardial ischemia
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
JP2014521958A (ja) * 2011-07-28 2014-08-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 胸腔内液若しくは漿液と関連する腫瘍細胞の特徴づけによる癌の診断方法
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
CN103122390B (zh) * 2013-03-07 2015-04-08 上海市疾病预防控制中心 Frat1基因作为检测甲状腺癌的血清标志物及其应用
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN103866039B (zh) * 2014-04-04 2015-05-27 厦门大学 人类甲状腺癌组织基因特异位点甲基化水平检测引物及其应用
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP2977759B1 (en) * 2014-07-25 2017-07-12 Serum Institute of India Private Limited Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
LT3280441T (lt) 2015-04-07 2021-11-25 Alector Llc Anti-sortilino antikūnai ir jų naudojimo būdai
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
CA3051488A1 (en) * 2017-01-24 2018-08-02 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
EP3635399B1 (fr) * 2017-06-08 2025-10-29 Gnaho, Sylvain Méthode d'isolement et de détection de cellules souches cancéreuses
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
PE20210186A1 (es) 2018-07-13 2021-02-02 Alector Llc Anticuerpos anti-sortilina y metodos para su uso

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1420785A (zh) * 2000-02-29 2003-05-28 赛福伦公司 采用抗神经营养蛋白剂治疗癌症的方法
WO2004040312A2 (fr) * 2002-10-28 2004-05-13 bioMérieux Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2004056385A2 (en) * 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
WO2005076695A2 (en) * 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076942A2 (fr) 2002-03-13 2003-09-18 Biomerieux Quantification de cellules tumorales circulantes issues de cancers solides
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1420785A (zh) * 2000-02-29 2003-05-28 赛福伦公司 采用抗神经营养蛋白剂治疗癌症的方法
WO2004040312A2 (fr) * 2002-10-28 2004-05-13 bioMérieux Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2004056385A2 (en) * 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
WO2005076695A2 (en) * 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Descamps等.Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.1998,第273卷(第27期),16659-16662. *

Also Published As

Publication number Publication date
JP5792121B2 (ja) 2015-10-07
FR2896881B1 (fr) 2008-04-18
JP5091876B2 (ja) 2012-12-05
JP2009525478A (ja) 2009-07-09
US9061045B2 (en) 2015-06-23
WO2007088305A1 (fr) 2007-08-09
CN101395478A (zh) 2009-03-25
US20090068200A1 (en) 2009-03-12
EP1982192B1 (fr) 2014-03-26
FR2896881A1 (fr) 2007-08-03
US20110293636A1 (en) 2011-12-01
EP1982192A1 (fr) 2008-10-22
US20130171173A1 (en) 2013-07-04
ES2471126T3 (es) 2014-06-25
JP2012211148A (ja) 2012-11-01
CN103446585A (zh) 2013-12-18
US8008009B2 (en) 2011-08-30

Similar Documents

Publication Publication Date Title
CN101395478B (zh) 用于体外诊断癌症具体是乳腺癌、甲状腺癌或肺癌的ProNGF测定的方法以及ProNGF的治疗用途
Rajamanickam et al. Selective targeting of the TLR4 co-receptor, MD2, prevents colon cancer growth and lung metastasis
US10618954B2 (en) CKAP4-molecular-targeted antitumor agent
Wei et al. Activation of vitamin D/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expression
AU2003285472B2 (en) Method for NGF assay for in vitro diagnosis of breast cancer and therapeutic use
US20240174762A1 (en) Methods, compositions and uses for targeting sema7a in the diagnosis and treatment of health conditions
WO2005084708A1 (ja) Ｃｘｃｒ３阻害剤を含有する医薬組成物
EP4532549A1 (en) Methods, compositions and uses for sema7a monoclonal antibodies
Gassler et al. Expression of calnexin reflects paneth cell differentiation and function
US7026454B1 (en) Neuroendocrine marker of prostate cancer and method for producing same
He et al. Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer
CN120801712B (zh) 检测、抑制微肽miPEP70的试剂或罗氏菌素的应用
CN120485120A (zh) 靶向lims2表达在抑制肺腺癌发展中的应用
KR102143974B1 (ko) 라파티닙 내성 암의 예방 또는 치료용 조성물
Wei et al. Activation of vitamin D/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expression
Wu et al. Chronic stress-induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis
KR101222587B1 (ko) 재발암, 내성암 또는 암전이 치료용 조성물
AU2002344775A1 (en) Neuroendocrine marker for cancer and method for producing same
WO2016155420A1 (zh) 特异性靶向wnt16b的抗体在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant